Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study published in The American Journal of Managed Care® (AJMC®) was highlighted in an article from mHealth Intelligence. The study, “A Cost-Effectiveness Analysis of Cardiology eConsults for Medicaid Patients,” found that a randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional fee-for-service consultations.
The National Pharmaceutical Council’s Wednesday CER Daily Newsfeed included an editorial published in the February 2019 issue of AJMC®. The editorial, “The Drug Pricing Iceberg: More Than Meets the Eye,” argues that policies that reduce prices but do not lower consumers’ out-of-pocket costs will not address the main challenge facing most Americans. The editorial was also featured in a press release from the University of Michigan’s Center for Value-Based Insurance Design, which is directed by A. Mark Fendrick, MD, the editorial’s lead author and co-editor-in-chief of AJMC®.
ADVANCE’s article on virtual visits focused on a study published in the January issue of AJMC®, “Patient and Clinician Experience With Telehealth for Patient Follow-up Care,” which demonstrated that for established patients, virtual video visits can be used for effective follow-up and enhanced convenience when compared with traditional office visits.
An article from Mind Body Green on yoga cited the AJMC® article “Restorative Yoga Better Than Stretching for Trimming Subcutaneous Fat in Overweight Women.” The article covered a session from the 73rd Scientific Sessions of the American Diabetes Association on a study showing that restorative yoga practitioners lost significantly more subcutaneous fat over the initial 6 months of the study period and kept losing it during a maintenance period with less direct supervision.
OBR Oncology’s Monday newsfeed included an article from AJMC®’s sister site, The Center for Biosimilars® (CfB). The article, “More Research Finds Low Awareness of Biosimilars Among Oncology Providers,” covered a survey that found that while a majority of respondents said they were at least somewhat familiar with current developments in oncology biosimilars, analyses of open-ended definitions showed that just 1 respondent could fully define a biosimilar. A second newsfeed included the CfB article “Sales of Oncology Reference Products Far Outpace R&D Costs, Study Finds,” which covered a study that found some stakeholders have expressed skepticism about whether research and development costs are indeed in line with the prices that drug makers charge.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More